Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/rth2.12115 http://scihub22266oqcxt.onion/10.1002/rth2.12115 C6046593!6046593!30046748     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Res+Pract+Thromb+Haemost 2018 ; 2 (3): 439-49 Nephropedia Template TP {{tp|p=30046748|t=2018. Novel aspects of antiplatelet therapy in cardiovascular disease |pdf=|usr=}}{{30046748}} gab.com Text Novel aspects of antiplatelet therapy in cardiovascular disease JO: Res Pract Thromb Haemost http://www.kidney.de/pget.php?&tw=1&pmid=30046748 #FOAvip Antiplatelet therapy is a cornerstone in the secondary prophylaxis of adverse cardiovascular events such as myocardial infarction and stroke. The cyclooxygenase inhibitor aspirin remains the most frequently prescribed antiplatelet drug, followed by adenosine diphosphate P2Y12 receptor blockers. Glycoprotein IIb?IIIa antagonists are intravenously available antiplatelet agents preventing platelet?to?platelet aggregation via the fibrinogen receptor. The thrombin receptor inhibitor vorapaxar allows the targeting of yet a third pathway of platelet activation. Despite the advent of novel agents and major advances in antiplatelet treatment over the last decade, atherothrombotic events still impair the prognosis of many patients with cardiovascular disease. Consequently, antiplatelet therapy remains a field of intense research and a large number of studies on its various aspects are published each year. This review article summarizes recent developments in antiplatelet therapy in cardiovascular disease focusing particularly on the duration of dual antiplatelet therapy, new treatment regimens, the role of platelet function testing, and potential future targets of antiplatelet agents. Twit Text FOAVip Novel aspects of antiplatelet therapy in cardiovascular disease ????Res Pract Thromb Haemost http://www.kidney.de/pget.php?&tw=1&pmid=30046748 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=30046748 #FOAvip English Wikipedia <ref>{{Cite pmid|30046748}}</ref> Novel aspects of antiplatelet therapy in cardiovascular disease #MMPMID30046748 Gremmel T; Michelson AD; Frelinger AL; Bhatt DL Res Pract Thromb Haemost 2018[Jul]; 2 (3): 439-49 PMID30046748show ga Antiplatelet therapy is a cornerstone in the secondary prophylaxis of adverse cardiovascular events such as myocardial infarction and stroke. The cyclooxygenase inhibitor aspirin remains the most frequently prescribed antiplatelet drug, followed by adenosine diphosphate P2Y12 receptor blockers. Glycoprotein IIb?IIIa antagonists are intravenously available antiplatelet agents preventing platelet?to?platelet aggregation via the fibrinogen receptor. The thrombin receptor inhibitor vorapaxar allows the targeting of yet a third pathway of platelet activation. Despite the advent of novel agents and major advances in antiplatelet treatment over the last decade, atherothrombotic events still impair the prognosis of many patients with cardiovascular disease. Consequently, antiplatelet therapy remains a field of intense research and a large number of studies on its various aspects are published each year. This review article summarizes recent developments in antiplatelet therapy in cardiovascular disease focusing particularly on the duration of dual antiplatelet therapy, new treatment regimens, the role of platelet function testing, and potential future targets of antiplatelet agents. äNovel aspects of antiplatelet therapy in cardiovascular disease (epmc).pdf DeepDyve Pubget Overpricing